disclosed that its wholly-owned US subsidiary Lupin Pharmaceuticals Inc. has reached a $30 million settlement with Humana Inc. in antitrust litigation related to alleged anticompetitive behavior in generic pharmaceuticals. The subsidiary denies all allegations but chose to settle to avoid litigation costs and uncertainties, with the settlement amount already accounted for in previous financial results. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.